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Abstract
Pre-treatment or early intra-treatment prediction of patients with head and neck squamous cell carcinomas
(HNSCC) who are likely to have tumours that are resistant to chemoradiotherapy (CRT) would enable treatment
regimens to be changed at an early time point, or allow patients at risk of residual disease to be targeted for more
intensive post-treatment investigation. Research into the potential advantages of using functional-based magnetic
resonance imaging (MRI) sequences before or during cancer treatments to predict treatment response has been
ongoing for several years. In regard to HNSCC, the reported results from functional MRI research are promising
but they have yet to be transferred to the clinical domain. This article will review the functional MRI literature in
HNSCC to determine the current status of the research and try to identify areas that are close to application in
clinical practice. This review will focus on diffusion-weighted imaging (DWI) and dynamic contrast-enhanced
MRI (DCE–MRI) and briefly include proton magnetic resonance spectroscopy (1H-MRS)and blood oxygen level
dependent (BOLD) MRI.
Keywords: MRI, DWI, DCE, MRS, Head and neck, Cancer, Squamous cell carcinoma, Radiotherapy, Chemotherapy,
Response
Background
Head and neck squamous cell carcinoma (HNSCC) is
the most common cancer in the head and neck. The two
main modalities of treatment with curative intent for
patients with advanced stage HNSCC are surgery or
chemoradiotherapy (CRT). Over the past decade the
non-surgical approach has become more popular because
of the better organ preservation, but not all HNSCCs
respond to CRT and approximately 25–30 % of patients
will fail treatment at local or nodal sites in the head and
neck. The successful pre-treatment identification of
patients with resistant tumours in the head and neck
would allow the CRT regimes to be modified or changed
to a surgical approach. In addition intra-treatment scanning
is already under evaluation to adapt radiotherapy (RT)
fields to the changing size of the tumour [1] providing an
opportunity to monitor early treatment response and adjust
CRT regimes accordingly. Even if treatment is unaltered
the identification of primary or nodal sites at risk of treat-
ment failure would allow those sites to be targeted for more
aggressive post-treatment investigation, so that residual
cancers can be identified while they are still amenable to
salvage surgery.
Computed tomography (CT), fluorine-18-fluorodeoxy
glucose-positron emission tomography (18FDG-PET)/CT
and magnetic resonance imaging (MRI) are used to
identify resistant HNSCCs. All three imaging modalities
are well established in routine clinical practice for staging
head and neck cancer, planning treatment and assessing
post treatment response. Each imaging modality has its
own merits the discussion of which is beyond the scope of
this review. This review will focus instead on MRI which
produces both anatomical and functional information, and
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is ideally suited to serial scanning, including repeat scan-
ning early in the course of treatment. In common with all
anatomical-based imaging, the anatomical MRI sequences
have limitations in predicting treatment response and in
monitoring response, hence the current interest in adding
functional-based MRI sequences to the standard MRI
examination protocol.
Functional MRI head and neck cancer research has been
ongoing for more than 10 years, but there are many
challenges still to be faced before functional MRI can be
transferred from the research to the clinical domain. This
article will review the current status of functional MRI
techniques in HNSCC for pre-treatment and early intra-
treatment prediction of response, with the emphasis on
diffusion-weighted imaging (DWI) and dynamic contrast-
enhanced MRI (DCE–MRI) and a brief inclusion of proton
magnetic resonance spectroscopy (1H-MRS) and blood
oxygen level dependent (BOLD) MRI.
Main text
Functional MRI in HNSCC
Functional MRI is a technically challenging examination to
perform on patients with head and neck cancer, because
acquisition is hampered by artefacts, including susceptibility
artefacts and those related to movement from coughing,
swallowing and breathing. Moreover, the acquisition pa-
rameters have yet to be standardized across centres, and
even when similar protocols are used reproducibility can be
problematic. Once the data has been acquired there is
variability in the methods of analysis. This includes issues
such as whether to analyse the primary tumour or nodal
metastases, where to place the regions of interest (ROI),
and whether to use programs that are developed “in-house”
or by produced by the different vendors data. Data obtained
from the entire tumour volume is more representative of
the tumour, compared with data obtained from small ROIs
within the tumour or from a ROI encompassing the largest
cross-sectional tumour area, but even so most studies have
reported only the mean value of the functional parameter,
which does not fully reflect tumour heterogeneity. To ana-
lyse tumour heterogeneity pixel by pixel analysis is being
used because it enables functional data to be displayed as a
histogram and provides additional parameter measures
such as percentiles, volumes of parameters in a defined
range, and those measures that reflect the shape of the dis-
tribution curve. The drawbacks of these sophisticated
methods of analysis are that they are more technically chal-
lenging and it is difficult to isolate a single functional par-
ameter measure that consistently predicts outcome.
Furthermore, an array of treatment endpoints has been
used to analyse the predictive value of each functional
MRI parameter. These endpoints include a change in
tumour size post-treatment which may not necessarily
predict clinical outcome, and tumour relapse in the head
and neck which preferably is assessed over a follow-up
period of at least 2–3 years when the vast majority of resis-
tant HNSCCs are known to recur. Relapse at specific
primary or nodal sites in the head and neck are valuable
endpoints for studies that are designed to influence intra-
treatment adaptive therapies or identify sites at risk of post-
treatment residual disease. These are the endpoints that are
of greater interest to the radiologist and are especially valid
for head and neck MRI. However, many studies use more
general endpoints such as relapse at any site including
distant sites, or survival including overall, disease-specific,
disease-free, progression-free and local relapse-free survival.
In summary, for any given functional MRI technique
variable methods are used for image acquisition, image
analysis and data correlation. Literature comparison is
therefore not straightforward because a range of diffe-
rent functional parameter measures, and their respective
thresholds, have been reported as predictors of outcome
based on a range of different treatment outcomes. It is
also worth noting that many functional MRI studies do
not incorporate non-radiological confounding factors into
the analysis, such as the human papilloma virus (HPV)
status, which is an important independent predictor of the
HNSCC outcome. These issues will be further explored
below in relation to each functional modality.
Diffusion-weighted imaging (DWI)
Pre-treatment DWI for prediction of treatment response
HNSCCs with high stromal content, low cellularity (lower
proliferation), micronecrosis and negative HPV status are
associated with resistance to treatment and poor outcome.
These tumour characteristics decrease diffusion restriction
of water molecules in HNSCC, as reflected by higher
apparent diffusion coefficients (ADC) [2–4]. Therefore, it
is hypothesised that high tumour ADC is a predictor of
poor outcome. However, an argument could also be made
for a low ADC being a predictor of poor treatment
response, based on the observation that poorly differen-
tiated HNSCCs have lower ADCs than well differentiated
HNSCCs [5–8] and poorly differentiated HNSCCs are
more likely to spread to regional and distant sites. Cur-
rently the reported DWI results seem to favour the high
mean ADC as the predictor of poor treatment response
[9–14] (Fig. 1a, b). Three studies have evaluated tumour
sites in the head and neck and found that primary
tumours with primary failure [10, 11] and nodal metas-
tases with nodal failure [9] showed significantly higher
mean pre-treatment ADCs than tumours with control at
those sites. These studies were able to identify cut-off
thresholds but the reported thresholds have a broad range
of > 0.79 to 1.1 × 10−3 mm2/s, two obtained from b values
ranging from 0–1000 s/mm2 [9, 11] and the other from
300–1000 s/mm2 [10]. Another three studies included
data from distant site relapse or death in the calculation of
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clinical outcome, and these studies found high ADC values
were predictors of disease relapse at any site [12], rate of
3 year regional control (ADC threshold of 1.14 × 10−3
mm2/s) [13], and disease free survival (ADC threshold of
1.51 × 10−3 mm2/s) [14]. Four further studies also found
higher ADC values [15–17] or higher D values (pure diffu-
sion values from intravoxel incoherent motion, (IVIM))
[18] in unfavourable compared to favourable outcome
groups, but the results of these four studies did not reach
significance for predicting failure at head and neck sites
[15, 16, 18] or failure at any site in the body [17]. Moreover,
a study by Nakajo et al. [19] found the opposite finding to
the studies above, a high ADC being a predictor of better
outcome based on two-year disease free survival.
Most DWI studies exclude the macroscopic necrotic
regions of a tumour from the analysis, but HNSCCs are
still heterogeneous tumours and the use of the mean ADC
value has limitations. To overcome these limitations fur-
ther research is required to find ways to analyse different
populations of tumour cells within HNSCC. This includes
using parameters such as ADC min [20] with one recent
study by Preda et al. [21] finding a high ADC min,
obtained from one standard deviation below the mean,
was a significant predictor of poor disease-free-survival.
There are three further variables that need to be consi-
dered when comparing the DWI results in the literature.
The first variable relates to the head and neck tumour site
chosen for data acquisition. A study by Noij et al. [14] in
the same patient population found that data acquired
from nodal sites were predictive of outcome, whereas data
acquired from primary sites were not. The second variable
relates to the choice of b values for DWI acquisition and
analysis. Recent studies have shown that mean ADCs
obtained from high b value ranges of 300/500–1000 s/
mm2 (“pure” diffusion) are more predictive of treatment
response than mean ADCs obtained from low b value
ranges of 0–100/300 s/mm2 (“perfusion-related” diffusion)
[10, 12]; but even within the higher range one study has
shown mean ADCs are predictive at 0–750 s/mm2 but are
not predictive at b 0–1000 s/mm2 [14]; and another study
has shown mean ADCs are predictive at b 0–2000 s/mm2
but are not predictive at b 0–1000 s/mm2 [22]. The third
variable relates to the variability of ADC values with
different MRI systems and sequences that has been
reported in some studies [23]. Therefore, further research
includes identifying the best tumour sites in the head and
neck to select for functional imaging, the optimum range
of b values for DWI acquisition and analysis, and the
optimum ADC parameters and thresholds.
Intra-treatment DWI for prediction of treatment response
As response adapted therapy becomes more widespread
in cancer management there will be greater interest in
performing intra-treatment scanning. A rise in ADC
occurs in the first few weeks after the start of HNSCC
treatment and there is now evidence to show the percen-
tage (%) rise in ADC is a predictor of treatment response.
Four studies have shown a smaller % rise in the mean
ADC 1–3 weeks after the start of treatment in patients
with disease failure compared to those with disease con-
trol [9, 15, 16, 24]. Three of these studies found thresholds
of < 14–24 %, were predictors of treatment failure in head
and neck sites using clinical outcome data with follow-up
for at least 2 years [15, 16, 24]. This approach is promising
because the % ADC change could be more reproducible
across centres than absolute ADC values, but further
research is required to confirm the optimum % change
threshold for clinical use. In the future serial DWI of
Fig. 1 a & b. Pre-treatment DWI for prediction of CRT response. a Pre-treatment ADC map of a squamous cell carcinoma of the tongue (arrows)
with a low ADC (0.73 × 10−3 mm2/s) in a tumour with local control; b Pre-treatment ADC map of a squamous cell carcinoma of the tongue
(arrows) with a high ADC (1.10 × 10−3 mm2/s) in a tumour with local failure
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HNSCC will provide an opportunity to closely monitor re-
sponse not only in the early treatment phase but through-
out treatment. In this regard it has been observed that
after the initial early ADC rise a subsequent ADC fall
predicts locoregional failure, it is postulated that this ADC
fall is caused by the repopulation of cancer cells [25]
(Fig. 2a-c). However, it is very important to exclude
frankly necrotic areas from ADC analysis because sterile
areas of necrosis may take longer to resolve than solid
areas, and in the interim the necrosis may become orga-
nised and show a fall in the ADC value. Therefore, it is
critical to assess the ADC map in conjunction with the
anatomical-based MRI sequences to identify sites of
necrosis that need to be excluded from ADC analysis
Furthermore with time the development of mature scar
tissue may also decrease the ADC value [26].
More sophisticated methods of intra-treatment analysis
which take into account the heterogeneity of treatment
induced-changes within a tumour have shown promising
results. One such method used parametric response maps
to monitor the change in the volume of ADC subsets [27]
while another analysed the shape of the ADC distribution
curve two weeks after the start of treatment and found
tumour sites with local control had curves skewed to-
wards the high ADC values and were more heterogeneous
with a broader peak, compared to tumour sites with local
failure (Fig. 3a-f) [15]. Furthermore, DWI may have an
important role in the evaluation of treatment response of
the new molecular targeted agents such as the antian-
giogenic agent Bevacizumab which is a monocolonal anti-
body that inhibits vascular endothelial growth factor
(VEGF). This factor is present in HNSCCs and its inhi-
bition could be valuable in the deintensification of CRT
regimes in HPV related tumours. Drug trials of these
agents in combination with CRT regimes are underway in
HNSCC, but is known already from research into gliomas
that Bevacizumab may produce a pseudo-response on
imaging, whereby a reduction in the enhancing compo-
nent of the tumour and surrounding oedema may mask
progression of the underlying tumour. In this scenario the
presence of persistent or increasing restriction of diffusion
may be a better marker of disease progression.
Summary of the role of DWI
DWI research points to high pre-treatment mean ADC and
a low % rise in ADC early intra-treatment being indicators
of poor outcome. Intra-treatment scanning is likely to
become more important in clinical management and one of
the main advantages of DWI over DCE or PET/CT is that
it does not require an injection of gadolinium or FDG. In
this regard the early % change in mean ADC for predicting
response at tumour sites in the head and neck is one of the
most promising clinical applications for DWI, once a cut-
off threshold has been confirmed. However, further work is
needed to improve quality assurance across different MRI
scanners, standardise the DWI protocol, especially in rela-
tionship to the choice of b values, and develop more
sophisticated methods for analysing heterogeneous treat-
ment induced changes. In addition, ongoing technological
advances continue to reduce susceptibility and motion
artefacts associated with DWI in the head and neck.
Dynamic Contrast-Enhanced MRI (DCE-MRI)
Pre-treatment prediction
Vascular HNSCCs are thought to have a better treatment
response compared to less vascular HNSCCs (Fig. 4a, b),
Fig. 2 a, b & c. Change in DWI over treatment for prediction of CRT response. ADC maps of a hypopharyngeal SCC (arrows) with local failure;
a Pre-treatment, b two weeks intra-treatment, c 6 weeks post-treatment. The ADC shows the expected initial early rise in ADC but there is a later
fall in ADC (believed to be due to repopulation of tumour cells). {Image reproduced from: King AD, Mo FK, Yu KH, et al. (2010) Squamous cell
carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response. Eur Radiol 20:2213-20.}
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because of better delivery of the chemotherapeutic agents
and greater radiosensitivity. On the other hand vascular
tumours may have a poorer outcome because it is thought
they have greater metastatic potential. Vascular-related pa-
rameters of HNSCC can be studied using DCE-MRI
which evaluates the passage of a standard gadolinium-
based MRI intravenous contrast agent in the intravascular
and extravascular extracellular space of the tumour. These
can be measured using semiquantitative techniques which
analyse the time-signal intensity curve, or quantitative
techniques such as the pharmacokinetic models (PKM)
described by Tofts [28]. Compared with DWI, DCE
Fig. 3 a-f. Analysis of the early intra-treatment ADC distribution curve for prediction of CRT response. ADC maps of a tonsil SCC (ROI) with local
control; a pre-treatment, b two weeks intra-treatment, c ADC distribution curve pre-treatment (solid line) and two weeks intra-treatment (dashed line).
ADC maps of a tongue SCC (ROI) with local failure; d pre-treatment, e two weeks intra-treatment, f ADC distribution curve pre-treatment (solid line)
and two weeks intra-treatment (dashed line). The ADC distribution curve of the tumour with local failure shows less movement to the right side,
(smaller increase in ADC mean) and a high skewness (skewness has fallen, but the short tail still remains on the positive left side) and the curve still
has an acute peak with a high ADC kurtosis (kurtosis has fallen only slightly and remains high). {reproduced with permission of Radiology and
[King AD, Chow KK, Yu KH, et al. Head and neck squamous cell carcinoma: diagnostic performance of diffusion-weighted MR imaging for the
prediction of treatment response. Radiology. 2013 Feb;266:531–538]}
Fig. 4 a & b. Pre-treatment DCE-MRI for prediction of CRT response. a Pre-treatment Ktrans map of a squamous cell carcinoma of the tongue (arrows)
with a high Ktrans (0.87 min−1) in a tumour with local control; b Pre-treatment Ktrans map of a squamous cell carcinoma of the tongue (arrows) with a
low Ktrans (0.29 min−1) in a tumour with local failure
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provides more potential functional parameters for analysis
but the data acquisition is more challenging, especially
when using PKMs, which have many technical problems
that have yet to be ironed out, including the accurate
measurement of the arterial input function. Currently the
Ktrans min−1 (the volume transfer constant between the
blood plasma and extracellular extravascular space) ob-
tained from PKM appears to be one of the most consistent
DCE parameters to show a correlation with outcome.
Most studies suggest high Ktrans values in tumours with a
good response [13, 17, 29–32], one of which acquired
functional data from the primary tumour sites [29], while
the other five evaluated metastatic nodes. However, vari-
ous outcome measures were used and clinical thresholds
were reported in only three of these studies ranging
from > 0.41 to 0.84 min−1[13, 29, 31]. Moreover, two pre-
treatment DCE-MRI studies were unable to show any
correlation between Ktrans [33] or blood volume and blood
flow [34] and outcome. Therefore, at present the data for
pre-treatment DCE-MRI seems to be insufficient to allow
translation to clinical practice.
Intra-treatment prediction
There is less reported research related to intra-treatment
monitoring using DCE-MRI compared to DWI possibly
because DCE-MRI requires an intravenous injection of a
contrast agent. There is some early work in tumour
xenografts to suggest a rise in tumour Ktrans may occur
over the first few days of treatment [35], and in human
subjects to suggest a rise in plasma flow at two weeks
[36]. It is postulated that an early rise in Ktrans is due to
damage to the blood vessels causing them to temporarily
become leakier, which potentially could increase the
delivery of chemotherapeutic agents into the tumour.
Indeed a few reports suggest a fall in Ktrans & area under
the gadolinium concentration-time curve (AUGC) is
associated with poor overall survival [37], while an early
rise in blood volume is associated with local control [34].
However, further research is required, especially as results
may be influenced by different therapeutic modalities and
regimes including the use of anti-angiogenic agents.
Summary of the role of DCE-MRI
DCE-MRI is an even more challenging functional technique
to perform in patients with HNSCC than DWI, and it has a
greater range of methods and functional parameters for
analysis. Research points to better assess treatment re-
sponses in tumours with higher vascular-related parameters
HNSCCs, a high pre-treatment Ktrans being predictive of a
good response, although clinically useful thresholds have
yet to be established. Intra-treatment monitoring is promis-
ing but still at a relatively early stage of research.
Proton Magnetic Resonance Spectroscopy (1H-MRS) and
Blood Oxygen Level Dependent (BOLD) MRI
1H-MRS was one of the first functional techniques to be
assessed in the characterisation of tumours in the head
and neck, but it remains a challenging technique in this
region of the body, and in regard to pre-treatment predic-
tion and intra-treatment monitoring of response there is a
paucity of a research in this area when compared to DWI
and DCE-MRI. One in vitro study of tumour specimens by
Bezabeh et al. [38] has shown significantly elevated pre-
treatment choline-to-creatine ratios in a poor response
group, but these findings could not be corroborated in an
in vivo human study using choline-to-creatine ratios as well
choline-to-water ratios [39]. This latter study was also
unable to show any predictive value for the 2 week intra-
treatment scan [39].
Tumour hypoxia reduces the effectiveness of CRT and
is associated with an unfavourable outcome in HNSCC
[40]. Tumour hypoxia may be evaluated by different
techniques which include non-invasive in vivo MRI using
BOLD which relies on the paramagnetic effect of blood
deoxyhaemoglobin to decrease the signal intensity on T2*
images. BOLD identifies changes in tumour oxygenation
while breathing oxygen or carbogen, which increases
diamagnetic oxyhaemoglobin leading to an increase in the
signal intensity within the tumour on T2* images. Although
BOLD imaging has been shown to be feasible [41, 42] and
T2* quantitative imaging may be sensitive and reproducible
[43] in HNSCCs the predictive value of BOLD MRI
currently is unknown.
Conclusions
Functional MRI research has identified parameters that
have the potential to predict CRT response in patients
with HNSCC either before the start of treatment or
during a course of treatment. High ADCs from DWI and
low Ktrans from DCE-MRI in pre-treatment head and neck
sites are associated with unfavourable treatment out-
comes, but clinical thresholds have yet to be established
and research into the optimum methods of data acquisi-
tion and analysis are still ongoing. In the future it is likely
that intra-treatment scanning will become more import-
ant in clinical management allowing modification of CRT
regimes or the cessation of ineffective treatments. In this
regard DWI, which does not require an intravenous injec-
tion of an exogenous agent, is the most promising tech-
nique and current results suggest that those tumours with
a low % rise in ADC early in the course of treatment are
more likely to fail treatment than those tumours with a
high % rise in ADC.
Future advances are likely to come from optimisation of
acquisition protocols, the development of more sophisti-
cated methods of analysis which take into account tumour
heterogeneity and allow serial intra-treatment changes to
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be monitored, and multiparametric imaging combining
not only the different functional MRI parameters but also
PET parameters on the new PET/MRI systems. However,
in order for functional MRI to make it into mainstream of
cancer management it must to be reproducible across
multiple centres. Working groups are looking into the qua-
lity assurance and standardization of methods, but more
work is needed to set up acceptable guidelines as functional
MRI evolves [44–46].
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